Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein

被引:28
作者
Trambas, C
Wang, ZM
Cianfriglia, M
Woods, G
机构
[1] Univ Tasmania, Discipline Pathol, Hobart, Tas, Australia
[2] Ist Super Sanita, I-00161 Rome, Italy
关键词
natural killer cells; P-glycoprotein; dye efflux; Western blot analysis; MDR1;
D O I
10.1046/j.1365-2141.2001.02885.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several lines of evidence including reverse transcription polymerase chain reaction, immunoreactivity and their ability to efflux rhodamine 123 have implied the existence of P-glycoprotein in natural killer (NK) cells. It has been a natural tendency to assume that NK-cell P-glycoprotein is identical to the P-glycoprotein of multidrug resistant (MDR) cell lines, however, the present study uncovered major differences. Functionally, NK cells demonstrated a restricted substrate profile, being unable to transport daunorubicin and calcein acetoxymethylester while efficiently transporting other P-glycoprotein substrates. Furthermore, physical differences in NK-cell P-glycoprotein were established by differential reactivity with P-glycoprotein antibodies. NK cells demonstrated strong reactivity with C494 and JSB-1, but did not react appreciably with C219. In addition, NK cells were unable to bind to the antibody MM4.17 unless they had been fixed and permeabilized, yet this antibody normally recognizes an extracellular epitope of P-glycoprotein. These differences culminated in the demonstration using Western analysis that NK cells did not express detectable levels of 170 kDa P-glycoprotein. Instead, NK cells expressed small-molecular-weight 'mini P-glycoprotein' products, of approximately 70 and 80 kDa. Collectively, these data indicate that the predominant P-glycoprotein species of NK cells are novel mini P-glycoproteins and not the classic P-glycoprotein of MDR models.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 35 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic β cells is mediated by a 65-kDa mdr-like P-glycoprotein [J].
Barg, S ;
Renström, E ;
Berggren, PO ;
Bertorello, A ;
Bokvist, K ;
Braun, M ;
Eliasson, L ;
Holmes, WE ;
Köhler, M ;
Rorsman, P ;
Thévenod, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5539-5544
[3]   EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS [J].
CHAUDHARY, PM ;
RONINSON, IB .
CELL, 1991, 66 (01) :85-94
[4]  
CHAUDHARY PM, 1992, BLOOD, V80, P2735
[5]   DIVERSE MULTIDRUG-RESISTANCE-MODIFICATION AGENTS INHIBIT CYTOLYTIC ACTIVITY OF NATURAL-KILLER-CELLS [J].
CHONG, ASF ;
MARKHAM, PN ;
GEBEL, HM ;
BINES, SD ;
COON, JS .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (02) :133-139
[6]  
CIANFRIGLIA M, 1994, INT J CANCER, V56, P153
[7]   Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells [J].
Davey, MW ;
Hargrave, RM ;
Davey, RA .
LEUKEMIA RESEARCH, 1996, 20 (08) :657-664
[8]  
DRACH D, 1992, BLOOD, V80, P2729
[9]   P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833 [J].
Egashira, M ;
Kawamata, N ;
Sugimoto, K ;
Kaneko, T ;
Oshimi, K .
BLOOD, 1999, 93 (02) :599-606
[10]  
GEORGES E, 1993, J BIOL CHEM, V268, P1792